28 research outputs found
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders
IFNGR/STAT1 signaling in recipient hematopoietic antigen presenting cells suppresses graft-versus-host disease
Absence of Interferon-γ Receptor (IFNGR) or Signal Transducer and Activator of Transcription 1 (STAT1) signaling in donor cells has been shown to result in reduced acute GVHD induction. In this study, we unexpectedly observed increased activation and expansion of donor lymphocytes in both lymphohematopoietic organs and GVHD target tissues of IFNGR/STAT1-deficient recipient mice, leading to rapid mortality following the induction of GVHD. Lipopolysaccharide (LPS)-matured bone marrow-derived Ifngr1-/-/Stat1-/- dendritic cells (BMDCs) were more potent allogeneic stimulators and expressed increased levels of MHC II and costimulatory molecules. Similar effects were observed in human APCs with knockdown of Stat1 by CRISPR/Cas9 and treatment with a JAK1/2 inhibitor. Furthermore, we demonstrated that the absence of IFNGR/STAT1 signaling in hematopoietic APCs impaired the presentation of exogenous antigens while promoting the presentation of endogenous antigens. In contrast, the indirect presentation of host antigens to donor lymphocytes was defective in IFNGR/STAT1-deficient donor-derived APCs in fully donor chimeric mice. The differential effects of IFNGR/STAT1 signaling on endogenous and exogenous antigen presentation could provide further insight into the roles of the IFN-γ/STAT1 signal pathway in the pathogenesis of GVHD, organ rejection, and autoimmune diseases
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders
Recommended from our members
Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Abstract
Background
Despite recent advances in treatment options, multiple myeloma (MM) remains incurable. We previously presented preliminary data from an ongoing Phase 1/2 trial (NCT03761108) demonstrating that REGN5458 (a BCMAxCD3 bispecific antibody) monotherapy had an acceptable safety and tolerability profile with early, deep, and durable responses in heavily pretreated patients (pts), with at least triple-refractory RRMM, (Madduri, ASH 2020, O291). Here we describe updated safety, overall response, and response durability in pts treated in the Phase 1 portion of this study.
Methods
The primary objectives of the Phase 1 portion of the study are to assess the safety, tolerability, and occurrence of dose-limiting toxicities of REGN5458 and to determine a recommended Phase 2 dose regimen (RP2DR). Key secondary objectives include: assessment of objective response rate as determined by the investigator, duration of response (DOR), and minimal residual disease status; pharmacokinetic (PK) evaluation; and characterization of immunogenicity. Pts with progressive RRMM, who were triple-refractory, or intolerant to prior lines of systemic therapy including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody are treated with REGN5458 monotherapy following a modified 3+3 dose-escalation design (4+3). Treatment consists of 16 weekly infusions of REGN5458, followed by q2w dosing, until disease progression. Response assessments are measured using modified International Myeloma Working Group criteria.
Results
As of data cut-off (June 10, 2021), 68 pts were treated with REGN5458 in the dose escalation cohort with full doses ranging from 3-400 mg. The median age at enrollment was 64 years (range, 41‒81) and 20.6% pts were ≥75 years. As per Revised International Staging System, stage was 1, 2 or 3 in 14.7%, 60.3% and 23.5% of pts respectively. Pts had a median of 5 prior lines of systemic therapy (range, 2-17) with the majority of pts (51.5%) being penta-refractory (see Table). The median duration of follow-up was 2.4 months (range, 0.1-20.8).
Treatment-emergent adverse events (TEAE) were reported in 66 pts (97.1%), and Grade (Gr) ≥3 TEAEs in 52 (76.5%) pts. The most frequent TEAEs were fatigue in 29 pts (42.6%), Gr 1/2 in 26 pts (38.2%), Gr 3 in 3 pts (4.4%); cytokine release syndrome (CRS) in 26 pts (38.2%), CRS was Gr 1 in 23 pts (33.8%) and Gr 2 in 3 pts (4.4%). No pt had Gr ≥3 CRS or discontinued treatment due to CRS. There were no Gr ≥3 neurotoxicity events. Nausea was reported in 22 pts (32.4%). The severity of nausea was Gr 1 in 23.5% of pts and Gr 2 in 8.8% of pts.
Treatment-related adverse events (TRAE) were reported in 56 patients (82.4%). The most frequent hematologic TRAE was neutropenia in 11 pts (16.2%), with Gr ≥3 severity in 9 of these pts (13.2%). The most frequent non-hematologic TRAEs were CRS (38.2%) and fatigue (20.6%). The safety profile was consistent across all dose levels, and there was no correlation between CRS and the full dose of REGN5458.
Responses were observed at all dose levels. Amongst pts treated at the 96 and 200 mg dose levels, the response rate was 73.3% (11/15). Across all dose levels, 92.6% (n=25) of all responders achieved at least a very good partial response and 48.1% (n=13) of responders had a complete response (CR) or stringent CR. Pts without extramedullary plasmacytomas (EMP) responded more frequently than those with EMP. The Kaplan-Meier estimated median DOR was not reached and the probability of DOR ≥8 months was 92.1% (95% confidence interval: 72.1, 98.0), with responses ongoing up to 19 months at the latest data cut-off.
Disease response was not impacted by level of BCMA expression in the core biopsy, as assessed by immunohistochemistry.
Additional PK and biomarker data will be available at the time of presentation. Updated safety and efficacy data will also be presented.
Conclusions
In this updated analysis of the first-in-human study, REGN5458 continues to show an acceptable safety and tolerability profile, with Gr 2 CRS in only 4.4% of patients, and no Gr ≥3 CRS or neurotoxicity events. No new safety signals were observed during the additional follow-up period. Early, deep, and durable responses were seen in triple- to penta-refractory patients with RRMM, with a 73.3.% response rate at the combined 96 and 200 mg dose levels. The Phase 2 portion of the study is currently recruiting.
Figure 1 Figure 1.
Disclosures
Zonder: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Research Funding; Alnylam: Consultancy; Janssen: Consultancy; Amgen: Consultancy; Caelum Biosciences: Consultancy; Intellia: Consultancy; Regeneron: Consultancy. Richter: BMS, Karyopharm, Antengene: Membership on an entity's Board of Directors or advisory committees; Adaptive biotechnologies: Speakers Bureau; Janssen, Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Tisch Cancer Institute: Icahn School of Medicine at Mount Sinai: Current Employment. Bumma: Amgen, Sanofi: Speakers Bureau; Janssen, Oncopeptides, Sanofi: Consultancy. Hoffman: BMS, Celgene: Honoraria. Bensinger: BMS, Janssen, Poseida, Regeneron, Trillium: Research Funding; Amgen, BMS, Janssen, Sanofi: Speakers Bureau. Xu: Regeneron Pharmaceuticals, Inc: Current Employment; Regeneron Pharmaceuticals, Inc: Current holder of stock options in a privately-held company. Chokshi: Regeneron Pharmaceuticals, Inc: Current holder of stock options in a privately-held company; Regeneron Pharmaceuticals, Inc: Current Employment. Boyapati: Regeneron Pharmaceuticals, Inc: Current Employment; Regeneron Pharmaceuticals, Inc: Current holder of stock options in a privately-held company. Sharma: Regeneron Pharmaceuticals, Inc.: Patents & Royalties: US17/112,564: Methods of Treating Multiple Myeloma with Bispecific anti-BCMA X anti-CD3 Antibodies (Status: Pending). Rodriguez Lorenc: Regeneron Pharmaceuticals, Inc: Current Employment; Regeneron Pharmaceuticals, Inc, Novartis Pharmaceuticals: Current holder of stock options in a privately-held company. Kroog: Regeneron Pharmaceuticals, Inc: Current Employment; Regeneron Pharmaceuticals, Inc: Current holder of stock options in a privately-held company. Lentzsch: Magenta Therapeutics: Current equity holder in publicly-traded company; Ossium Health: Consultancy; Caelum Biosciences: Consultancy, Current holder of individual stocks in a privately-held company; Oncopeptides: Consultancy; Sanofi: Consultancy, Research Funding; Karyopharm: Consultancy, Research Funding; Takeda: Consultancy; GSK: Consultancy; AbbVie: Consultancy; Celularity: Consultancy; Janssen: Consultancy; Kadmon: Current equity holder in publicly-traded company. Jagannath: Janssen Pharmaceuticals: Consultancy; Takeda: Consultancy; Legend Biotech: Consultancy; Karyopharm Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy; Sanofi: Consultancy.
OffLabel Disclosure:
The data described in the abstract will report on use of REGN5458 in a Phase 1 clinical trial of patients with relapsed/refractory multiple myelom
Recommended from our members
Poster: MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders
Recommended from our members
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease
PURPOSEThe aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.MethodologyAn interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members.RecommendationsBisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease
Purpose
The aim of the International Myeloma Working Group was to develop
practice recommendations for the management of multiple myeloma (MM)
-related bone disease.
Methodology
An interdisciplinary panel of clinical experts on MM and myeloma bone
disease developed recommendations based on published data through August
2012. Expert consensus was used to propose additional recommendations in
situations where there were insufficient published data. Levels of
evidence and grades of recommendations were assigned and approved by
panel members.
Recommendations
Bisphosphonates (BPs) should be considered in all patients with MM
receiving first-line antimyeloma therapy, regardless of presence of
osteolytic bone lesions on conventional radiography. However, it is
unknown if BPs offer any advantage in patients with no bone disease
assessed by magnetic resonance imaging or positron emission
tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL)
or pamidronate (PAM) is recommended for preventing skeletal-related
events in patients with MM. ZOL is preferred over oral clodronate in
newly diagnosed patients with MM because of its potential antimyeloma
effects and survival benefits. BPs should be administered every 3 to 4
weeks IV during initial therapy. ZOL or PAM should be continued in
patients with active disease and should be resumed after disease
relapse, if discontinued in patients achieving complete or very good
partial response. BPs are well tolerated, but preventive strategies must
be instituted to avoid renal toxicity or osteonecrosis of the jaw.
Kyphoplasty should be considered for symptomatic vertebral compression
fractures. Low-dose radiation therapy can be used for palliation of
uncontrolled pain, impending pathologic fracture, or spinal cord
compression. Orthopedic consultation should be sought for long-bone
fractures, spinal cord compression, and vertebral column instability.
(C) 2013 by American Society of Clinical Oncolog